Welcome to our dedicated page for Integer Holdings news (Ticker: ITGR), a resource for investors and traders seeking the latest updates and insights on Integer Holdings stock.
Integer Holdings Corporation reports news as a medical device contract development and manufacturing organization serving cardio and vascular, neuromodulation, and cardiac rhythm management markets. Company updates commonly cover sales trends, organic growth, product-line performance, adjusted earnings measures, debt and leverage, and outlook commentary tied to customer programs and new product activity.
Integer news also includes governance and capital-allocation developments, including board composition, shareholder engagement, share repurchase authorization, investor conference participation, and broader strategy updates. The company’s public identity includes the Greatbatch Medical and Lake Region Medical brands and engineering and manufacturing work for medical device customers.
Integer Holdings Corporation has elected three new directors to its Board: Sheila Antrum, Cheryl Capps, and Alvin (Tyrone) Jeffers, enhancing its manufacturing and healthcare expertise. Antrum brings over 40 years in medical operations, currently serving as COO at UCSF Health. Capps, with 35 years in supply chain management, is the SVP at Corning Inc. Jeffers, with 24 years in manufacturing, is VP of Global Manufacturing at SPX FLOW. Integer aims to leverage their diverse perspectives to drive growth and execute strategic initiatives.
Integer Holdings Corporation (NYSE:ITGR) is set to announce its financial and operational results for Q4 and full-year 2020 on February 18, 2021, at 8 a.m. ET. A conference call will follow at 9 a.m. ET, where management will discuss the results and other material information. Interested parties can participate via a domestic dial-in number or an international number. A replay of the call will be available for seven days post-event, and the call will also be accessible on the company's Investor Relations website.
Integer Holdings Corporation (NYSE: ITGR) has announced a significant expansion at its Alden, NY facility to increase production capacity for Xcellion® Lithium Ion rechargeable batteries. The expansion, which began in December 2020, aims to enhance battery production for applications in neuromodulation and cochlear devices. The project includes new manufacturing equipment and facility upgrades, expected to complete in 2021. This strategic investment is designed to meet the growing demands of Integer's cardiac and neuromodulation customers.
Integer Holdings Corporation (NYSE:ITGR) reported its third-quarter results for 2020, highlighting a sales decline of 22% to $236 million, with GAAP income down 1% to $30 million. Non-GAAP adjusted income fell 58% to $17 million, while adjusted EBITDA dropped 47% to $37 million. The company expects fourth-quarter sales to improve by $20-$35 million and projects a 200-300 basis point increase in adjusted operating income margin. Integer received a $28 million patent litigation judgment, aiding its debt reduction efforts, with net total debt decreasing to $747 million.
Integer Holdings Corporation (NYSE: ITGR) has secured approximately $28 million from a Federal Court ruling in its favor against AVX Corporation for patent infringement. This outcome allows Integer to reduce its net debt by about 4%. The company emphasizes its commitment to protecting intellectual property, which supports its goal of enhancing patient lives through innovative medical technologies. Integer is a leading manufacturer in the medical device outsourcing space, catering to several critical healthcare markets.
Integer Holdings Corporation (NYSE:ITGR) is set to release its third quarter 2020 financial and operational results on October 29, 2020, at 8 a.m. ET. Following the results announcement, a management webcast will be held at 9 a.m. ET to discuss the outcomes and additional forward-looking information. Investors can join the conference call using specific dial-in numbers provided. Integer, a leading medical device manufacturer, specializes in cardiac, neuromodulation, vascular, and orthopedics markets, offering innovative medical technologies.
Integer Holdings Corporation (NYSE:ITGR) reported second-quarter 2020 results, posting a 24% decline in sales to $240 million compared to the same quarter last year, attributed to the COVID-19 pandemic. GAAP income plummeted 99% to $0.4 million, while non-GAAP adjusted income fell 74% to $10 million. Despite the challenges, the company maintained ample liquidity and reduced total debt by $33 million to $770 million. Notable was the affirmation of a $27 million patent infringement ruling in its favor. Integer continues to adapt strategically to shifting demands.
Integer Holdings Corporation (NYSE: ITGR) will announce its Q2 2020 financial and operational results on July 30, 2020, at 8 a.m. ET. A webcast led by Integer management will follow at 9 a.m. ET. The call will cover forward-looking information and material updates. Investors can join via phone or through the Investor Relations section of Integer's website. Integer is a leading medical device manufacturer serving diverse markets, including cardiac and neuromodulation.
Integer Holdings Corporation (NYSE: ITGR) has achieved a significant legal victory as the U.S. Court of Appeals for the Federal Circuit confirmed a judgment of over $27M in its favor against AVX Corporation. This ruling comes after a lengthy patent infringement case initiated in 2013, where Integer's subsidiary, Greatbatch Ltd., accused AVX of infringing three patents related to vital medical device components for pacemakers and defibrillators. Senior VP, Elizabeth Giddens, expressed satisfaction with the outcome, marking it as a complete victory for the company.
Integer Holdings Corporation (NYSE: ITGR) announced a successful amendment to its senior secured credit facility amid the COVID-19 pandemic. This precautionary measure aims to enhance liquidity and support ongoing strategic investments and acquisitions. The amendment adjusts the covenant net leverage ratio from 4.00 to 1.00 to 4.75 to 1.00 for the period from Q3 2020 to Q2 2021, before stepping down to 4.50 to 1.00 for one quarter. The company will incur advanced and deferred amendment fees to consenting lenders as part of this arrangement, showcasing strong lender support.